PDUFA dates September 2018: FDA calendar and catalysts.
0 PDUFA dates fell in September 2018. The FDA calendar also recorded 7 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in September 2018
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
September 2018: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| September 7, 2018 | Cassipa (buprenorphine hydrochloride; naloxone hydrochloride) | TEVA | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 13, 2018 | Lumoxiti (moxetumomab pasudotox-tdfk) | IPHA | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 14, 2018 | Ajovy (fremanezumab-vfrm) | TEVA | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 27, 2018 | Emgality (galcanezumab-gnlm) | LLY | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 27, 2018 | Vizimpro (dacomitinib) | PFE | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 28, 2018 | Arikayce Kit (amikacin sulfate) | INSM | FDA approval | — | Approved | openFDA Drugs@FDA |
| September 28, 2018 | Libtayo (cemiplimab-rwlc) | REGN | FDA approval | — | Approved | openFDA Drugs@FDA |
September 2018: dated readouts
No events in this view.
Questions
What PDUFA dates are in September 2018?
0 PDUFA dates fell in September 2018. The FDA calendar also recorded 7 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.